The global systemic scleroderma treatment market size is expected to reach USD 1.9 billion by 2027, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 4.0% from 2020 to 2027. The market is largely attributable to the strong presence of therapies used off-label that include small molecule therapies including branded, generics, and OTC drugs.
The mix of several indications and drug classes engenders a fragmented space with multiple players. Johnson and Johnson Services, Inc. dominated the market with a share of 23.7% in the year 2019. United Therapeutics Corporation is the second biggest service provider in the space with a significant share in 2019. The other players such as F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, and Pfizer Inc. also have a significant share of the global market.
The on-label treatment is in the development phase. Major players with therapies undergoing clinical development are divided into two sorts. There are some developing new compounds, whereas certain other established players are seen repurposing their drugs (currently approved for other indications) for scleroderma use. In September 2019, Boehringer Ingelheim GmbH announced the U.S. FDA approval of Ofev for the treatment of interstitial lung disease in patients with systemic sclerosis.
Supplemental indication approval is one of the most common strategies adopted by pharmaceutical players thriving in the space. There are several pharmaceutical companies adopting strategies that favor the pharmaceutical industry in offsetting high development costs.
For instance, companies are developing promising product candidates such as Ziritaxestat, an autotaxin inhibitor from Galapagos NV in collaboration with Gilead Sciences, Inc. Furthermore, Horizon Therapeutics plc entered the space with the acquisition of Curzion Pharmaceuticals, Inc. in April 2020 that is developing HZN-825 and Tepezza.
Request a free sample copy or view report summary: Systemic Scleroderma Treatment Market Report
The immunosuppressors segment held the largest revenue share in 2019, followed by prostacyclin analogues
The high preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class will support its dominant share in this space
The U.S. held the majority of the revenue share in 2019. Expected label expansions and the expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs are expected to support market growth
Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma
Grand View Research has segmented the global systemic scleroderma treatment market based on drug class and region:
Systemic Scleroderma Treatment Drug Class Outlook (Revenue, USD Million, 2016 - 2027)
Phosphodiesterase 5 inhibitors - PHA
Endothelin Receptor Antagonists
Calcium Channel Blockers
Systemic Scleroderma Treatment Regional Outlook (Revenue, USD Million, 2016 - 2027)
List of Key Players of Systemic Scleroderma Treatment Market
Boehringer Ingelheim International GmbH
Gilead Sciences Inc.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."